Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-Concept, Open-Label Study Evaluating the Safety and Tolerability of Cilofexor in Subjects With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

NCT04060147 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04060147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04060147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-Concept, Open-Label Study Evaluating the Safety and Tolerability of Cilofexor in Subjects With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Terminated
Start date
October 17, 2019
Completion date
September 2, 2021
Enrollment
11 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

compensated cirrhosis, primary sclerosing cholangitis